A Study of AK130 in Patients With Advanced Malignant Tumors
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
A Phase I open label, dose-escalation and expansion study to evaluate the safety,
tolerability, pharmacokinetics and anti-tumor activity of AK130 (TIGIT/TGF-β bifunctional
fusion protein) in patients with advanced malignant tumors.